Integrating AI and ML Techniques in Modern Microbiology

Rabi Sankar Mondal[1*], Lamia Akter[2], Md Nazmul Alam Bhuiyan[1]

Abstract

The integration of artificial intelligence (AI) and machine learning (ML) into the field of microbiology is making a significant impact on both research and clinical practices. These technologies are helping us better understand microbial systems, improve diagnostic accuracy, speed up drug discovery, and tailor treatments to individual patients. Some exciting applications of AI in microbiology include helping with genome sequencing, predicting antimicrobial resistance, developing vaccines, and analyzing microbiomes. In industrial settings, AI is transforming quality control and safety in the pharmaceutical, food, and cosmetic industries. However, despite these advancements, there are still challenges that prevent us from fully realizing the potential of AI and ML in microbiology. Issues such as inconsistent data quality, the complexity of algorithms that can be difficult to interpret, a lack of regulatory guidelines, and ethical concerns surrounding data privacy and algorithm bias must be addressed. There is a pressing need for collaboration across various fields, transparent development of models, and cooperation among academic institutions and healthcare providers globally. Looking to the future, we can expect innovations in deep learning, hybrid modeling techniques, and the development of international standards and policies to drive further advancements. With responsible implementation and ongoing research, AI and ML are set to become essential tools in microbiology, offering innovative solutions to persistent challenges in healthcare, diagnostics, and environmental monitoring. This review focuses on the current uses, challenges, and future directions of AI in microbiology, highlighting the importance of ethical considerations, collaboration, and data-driven strategies to achieve meaningful and sustainable outcomes.

Keywords: Artificial intelligence, machine learning, microbiology, antimicrobial resistance, personalized medicine

Significance | AI and ML are revolutionizing microbiology by providing rapid and accurate insights that enhance research, diagnosis, and treatment.

*Correspondence. Rabi Sankar Mondal, Pompea College of Business, University of New Haven, West Haven, Connecticut, USA
Email: rabi.s.mondal@gmail.com

Editor Ahmed Obaid, Ph.D., And accepted by the Editorial Board July 22, 2025 (received for review April 29, 2025)

1. Introduction

The integration of Artificial Intelligence (AI) and Machine Learning (ML) techniques into modern microbiology is fundamentally transforming the field, enabling scientists to analyze complex biological systems more effectively, enhance diagnostics, and expedite the discovery of new drugs. These technologies are particularly crucial in addressing the challenges posed by the rapid increase in microbiological data generated through advanced techniques, such as next-generation sequencing (NGS), metagenomics, and high-throughput screening (Ali et al.,2022). By automating the analysis of this data and revealing patterns that are often too intricate for human analysis, AI and ML offer fresh insights into microbial diversity, behavior, and interactions, paving the way for groundbreaking advancements in both research and clinical microbiology. One of the most significant areas where AI is

Author Affiliation.
[1] Pompea College of Business, University of New Haven, West Haven, Connecticut, USA
[2] Department of Information Technology, Washington University of Science and Technology, Alexandria, Virginia, USA

Please Cite This:
Mondal, R. S., Akter, L., Bhuiyan, M. N. A. (2025). "Integrating AI and ML techniques in modern microbiology", Applied IT & Engineering, 3(1),1-10,10323

making an impact is in pathogen identification and classification. Machine learning models can rapidly analyze genomic and phenotypic data to identify microbial species, including rare or previously unknown ones (Altman et al., 2017). This capability is especially crucial in clinical environments, where timely and accurate diagnoses can significantly impact patient outcomes. Additionally, AI systems are being utilized to predict antimicrobial resistance (AMR) (Figure 1), a critical global health challenge. By examining patterns within genomic sequences and historical resistance data, these systems can forecast resistance trends and inform effective treatment strategies. AI and ML are also playing a pivotal role in the development of vaccines and drugs. Sophisticated algorithms can anticipate potential antigenic sites, model protein–protein interactions, and pinpoint druggable targets, thus significantly reducing the time and costs typically associated with drug discovery. The realm of personalized medicine stands out as another area where AI is making impressive progress. By analyzing individual patient data, which includes microbiome composition and genetic profiles, AI can help tailor treatments, leading to greater efficacy and fewer side effects (Alqaissi et al., 2023). Despite the promise these developments hold, integrating AI into microbiology faces several hurdles. One of the significant challenges is the quality and standardization of data. AI systems heavily rely on large, high-quality datasets to function effectively; any inconsistencies or gaps in the data can lead to unreliable predictions. Furthermore, there is often a lack of standardization in the collection, annotation, and storage of microbiological data, which complicates the training and validation of AI models (Bao et al.,2021).

Ethical and regulatory issues also present significant challenges (Table 2). The use of personal and clinical data raises concerns regarding data privacy, informed consent, and the potential for algorithmic bias. If these AI algorithms are trained on datasets that lack diversity, they may inadvertently perpetuate existing health disparities. The "black-box" nature of some AI systems complicates efforts to maintain transparency and accountability in decision-making, particularly in healthcare environments where trust and safety are crucial. Addressing these concerns is essential for building public and professional confidence in AI-driven microbiology (Becht et al.,2018). Developing strong data governance frameworks, maintaining transparency in algorithms, and fostering interdisciplinary collaboration are all necessary to ensure that AI technologies are implemented responsibly and equitably. Additionally, education and training programs should be established to equip microbiologists and healthcare professionals with the skills needed to collaborate effectively with AI tools. Understanding the historical background of AI in microbiology helps us appreciate the progress accomplished and the journey ahead. AI was formally established as a scientific field in 1956 during the Dartmouth Conference, where pioneers like John McCarthy envisioned machines capable of replicating human intelligence. Over the years, AI has undergone various waves of innovation, becoming increasingly sophisticated as the emergence of deep learning and neural networks has advanced its capabilities. In parallel, microbiology has evolved from basic studies of microbial morphology and physiology to more complex, data-intensive approaches that encompass genomic, proteomic, and metabolomic analyses (Benincà et al., 2023). The convergence of these two fields has been driven by the necessity to interpret the vast and intricate biological datasets available. The rise of big data in microbiology—from sequencing information to clinical records—has necessitated the development of advanced computational methods to effectively manage, analyze, and derive actionable insights. AI and ML have emerged as powerful tools to address these needs, facilitating quicker discoveries, more precise diagnostics, and streamlined research processes. Today, AI and ML are being integrated into microbiological workflows across research institutions, healthcare facilities, and biotechnology companies. These systems are not only automating routine tasks and optimizing lab operations, but also enabling predictive modeling of disease outbreaks and microbial behaviors (Bergmeir et al., 2012). However, for AI to fully realize its potential in microbiology, sustained investment in infrastructure, research, and policy development is crucial. The integration of AI and ML into modern microbiology marks a monumental shift, presenting unprecedented opportunities for advancing both scientific understanding and clinical care, and positioning us to address the challenges of the future better.

2. AI and ML Techniques in Microbiology

Artificial Intelligence (AI), particularly through its subset Machine Learning (ML), is becoming increasingly important in modern microbiology. These advanced computational techniques are being applied to a variety of applications, including the classification of microbes, the prediction of their behavior, and the analysis of how microorganisms interact with their environments. AI is also enhancing microscopy processes, enabling the automated identification and classification of microbes from complex visual data, which improves both accuracy and efficiency in diagnostics and research. One of the main benefits of AI and ML is their ability to analyze vast and complex datasets, uncovering meaningful patterns that traditional statistical methods might miss. In microbiology, this involves examining genomic, proteomic, and metagenomic data to identify pathogenic markers, monitor microbial evolution, and predict disease outbreaks (Cammarota et al., 2020). These methods also enable real-time analysis, which can lead to faster clinical decisions and more personalized treatment options. However, using AI and ML in microbiology comes with its own set of challenges. A significant issue is the availability and

Table 1. Applications of AI and ML in Microbiology and Healthcare

Application Area	Description	Reference(s)
Genome Sequencing	Enhances genome assembly, annotation, and discovery of new genes.	Cao et al., 2023
Antimicrobial Resistance Prediction	Identifies resistance patterns using genomic data and helps tailor treatment.	Gao et al., 2022; Shan et al., 2021
Drug Discovery & Repurposing	Accelerates target identification and reduces trial failures.	Tang et al., 2023; Deo, (2015).
Microbiome Analysis	Links microbial diversity with diseases and supports personalized medicine.	Goodswen et al., 2021; Tsuyuzaki et al., 2020
Diagnostic Imaging & Spectrometry	Uses ML to interpret microscopy and mass spectrometry data with precision.	Chadaga et al., 2022; Essalat et al., 2023
Vaccine Development	Predicts antigenic targets using immunological and biophysical data.	Deo, 2015
Forensic Microbiology	Automates the detection of microorganisms (e.g., diatoms), aiding in legal investigations and forensic analysis.	Chadaga et al., 2022
Smart Healthcare Tools	AI-powered systems for triage, symptom-checking, and home-based monitoring.	de Fátima Cobre et al., 2022

quality of data. Machine learning models require substantial amounts of high-quality, well-annotated data to operate effectively. Unfortunately, microbiological datasets can often be limited, diverse, or prone to errors, which can impact model performance and lead to inaccurate or biased conclusions. The situation is further exacerbated by inconsistent data collection methods and a lack of standardized formats across different laboratories (Campbell et al., 2021). To tackle these challenges, concerted efforts will be necessary to standardize and curate data, as well as to develop more robust AI algorithms. As this field evolves, fostering collaboration among microbiologists, data scientists, and bioinformaticians will be essential for fully realizing the benefits of AI and ML in microbiological research and clinical applications.

2.1 Applications of AI in Microbiology

Artificial Intelligence is transforming the field of microbiology in exciting ways, making it easier and more accurate to analyze and understand microbial data. One of the standout applications is in genome sequencing, where AI helps determine the precise nucleotide sequences in DNA. By automating tasks such as genome assembly, annotation, comparison, and visualization, AI not only accelerates these processes but also improves their accuracy (Cao et al., 2023). It can even assist researchers in uncovering new genes and biological pathways by sifting through vast and complex genomic datasets. In forensic microbiology, AI shows particular promise, especially in identifying and classifying microorganisms. Researchers can utilize AI for phylogenetic analysis, which enables them to trace the evolution of microbes and examine their genetic diversity. Furthermore, new automated systems for detecting diatoms are proving invaluable in forensic investigations, such as those related to drowning, by offering quick and reliable diagnostic support. AI's impact goes beyond genomics—it is also making waves in data processing and image analysis. Machine learning, intensive learning models, can analyze raw data, such as microscopy images and mass spectrometry outputs, with impressive precision. These models excel at identifying intricate patterns without requiring extensive manual input or predefined features. As a result, they enhance the accuracy and efficiency of classifying and identifying microbes, thereby reducing reliance on specialized expertise and accelerating research (Chadaga et al.,2022). The diverse ways AI is being applied in microbiology highlight its crucial role in advancing the field, from decoding complex genomes to interpreting intricate visual and spectral data. This progress is paving the way for faster diagnostics, better disease surveillance, and a deeper understanding of biology.

2.2 Machine Learning Paradigms in Microbiology

Machine learning has become an integral part of microbiological research, offering various approaches with distinct benefits. Two of the most common methods are supervised and unsupervised learning. In supervised learning, researchers train models using labeled datasets. This means the models learn from examples with known outcomes, which helps them predict results or classify data accurately. This technique is beneficial for tasks such as identifying different microbial species or predicting antimicrobial resistance (Chen et al., 2016). On the other hand, unsupervised learning works with unlabeled data. It helps scientists discover hidden patterns and group similar data points without any prior classifications, which is excellent for studying the diverse communities of microbes found in different environments. To address the challenges posed by both

Table 2. Challenges and Case Studies in AI Integration in Microbiology

Issue/Case Study	Details	Reference(s)
Data Quality & Standardization	Inconsistent and poorly annotated data affects model reliability.	Bao et al., 2021; Campbell et al., 2021
Algorithmic Bias	A lack of diversity in datasets can lead to biased results and exacerbate health disparities.	Becht et al., 2018; Fabian et al., 2011
"Black Box" Problem	Complex AI models lack transparency, raising concerns in clinical decision-making.	Feng et al., 2023
Public Trust & Ethics	Mistrust, data privacy concerns, and the ethical use of personal data are key barriers.	Fu et al., 2021
Industrial Applications	AI ensures microbial purity and enhances safety in the pharmaceutical, food, and cosmetics industries.	Ghosh et al., 2022
AMR Prediction Case (E. coli)	AI models successfully predicted antibiotic resistance in specific pathogens using genomic markers.	Gao et al., 2022
Microbiome-Disease Link	Machine learning has identified microbial shifts associated with chronic conditions such as diabetes and IBD.	Goodswen et al., 2021
Collaborative Gaps	Limited international collaboration restricts the exchange of data and knowledge.	Habgood-Coote et al., 2023

methods, semi-supervised learning has emerged as a valuable alternative. This approach combines a small amount of labeled data with a larger body of unlabeled data, allowing for better model performance, particularly in situations where gathering labeled datasets is challenging or expensive. Another interesting advancement is self-supervised learning, where the model generates its labels from the data during the training process (David et al., 2022). This means it can learn from raw biological data with minimal human input, making it especially helpful in large-scale microbiological studies. Reinforcement learning is another exciting area gaining traction, especially in medical microbiology. In this case, intelligent agents learn through trial and error by interacting with their environment. This method is being explored to optimize treatment strategies by simulating various therapeutic scenarios. For example, it shows promise in developing adaptive treatment plans for chronic infections, such as sepsis, hepatitis C, and HIV, allowing for a more personalized approach to patient care (Dawkins et al., 2022) (Figure 2). Collectively, these machine learning techniques provide researchers with powerful tools to delve deeper into complex microbiological data and develop more effective diagnostics and treatment options.

2.3 Applications of AI and ML in Microbiology and Healthcare

The integration of artificial intelligence (AI) and machine learning (ML) into microbiology and healthcare is transforming the way we approach medical practices. These advanced technologies are not just buzzwords; they are driving real progress in how we diagnose illnesses, develop treatments, discover new drugs, and improve public health services. By helping us analyze complex biological data more effectively, AI and ML are enabling more personalized and efficient healthcare (de et al.,2022). One of the most exciting areas where AI and ML are making a difference is in drug discovery and development. For instance, these technologies can rapidly sift through enormous amounts of genomic and clinical data, identifying potential new therapeutic targets. This capability not only reduces the time it takes to develop new drugs but also opens up innovative strategies for repurposing existing ones (Table 1). Moreover, AI can help address some significant roadblocks in drug development, such as predicting toxicity before drugs reach clinical trials. This means that new medications have a better chance of being safe and effective. In the realm of personalized medicine, AI and ML transform how healthcare professionals diagnose and treat infectious diseases. By analyzing specific microbial genomic data from patients, machine learning models can help create personalized treatment plans (Delafiori et al., 2021). This approach not only makes therapies more effective but also helps combat antibiotic resistance by targeting the unique genetic traits of pathogens. AI is also making healthcare more accessible and efficient. For example, AI-powered chatbots are now being utilized in healthcare systems to assist in triaging patients based on their symptoms. This reduces the burden on medical staff and allows for quicker preliminary guidance. Such tools can be particularly valuable when traditional doctor visits are delayed or unavailable. Additionally, AI is being integrated into assistive technologies for elderly and chronically ill patients—think smart home devices that can help manage medications, monitor vital signs, and remind patients about their health needs, extending care beyond the



Figure 1. Antimicrobial resistance driven by genetic exchange or mutation, leading to evolving resistance.

hospital walls. In microbial genomics, AI is playing a key role in identifying and characterizing pathogens. Advanced deep learning models are now capable of interpreting complex DNA sequences and accurately classifying microbial species. Tools like DeepMicrobes showcase this potential by efficiently analyzing short sequences from metagenomic samples, making microbial diagnostics faster and more accurate. This technology is crucial for understanding microbial ecosystems and their interactions, which is essential not just for infectious disease management but also for environmental microbiology. Vaccine development is another key area where AI is making significant strides (Deo et al., 2015). By combining machine learning with immunological and biophysical data, AI can quickly identify potential vaccine targets. This ability accelerates the discovery of vaccine candidates and helps address challenges related to the rising prevalence of drug resistance. AI's speed and precision are especially critical during public health crises and when responding to emerging infectious diseases, allowing for quicker design, testing, and deployment of vaccines. The applications of AI and ML in microbiology and healthcare are truly transformative (Essalat et al.,2023). They are optimizing drug development, personalizing treatments, improving diagnostic accuracy, and expanding access to healthcare. These advancements are not only reshaping the landscape of medical science; they also hold the promise of improved health outcomes for all of us in the future.

3. Challenges and Limitations of AI and ML in Microbiology

While artificial intelligence (AI) and machine learning (ML) hold great promise for advancing microbiology, their adoption in real-world applications presents significant challenges. It is crucial to tackle these hurdles to use them safely and ethically. One important issue is the lack of clear regulations and standards surrounding the use of AI in microbiology. For these technologies to be reliable and safe, we need adaptable and enforceable rules. Although some regulatory bodies are beginning to address these concerns, many processes related to approvals, safety evaluations, and performance assessments remain in flux, resulting in confusion and inconsistency. Ethical considerations also pose a significant challenge for the integration of AI in healthcare and microbiology (Fabian et al.,2011). We must carefully navigate issues like informed consent, data privacy, algorithmic bias, and transparency. As AI systems assume greater responsibility for managing sensitive patient data and influencing medical decisions, it becomes vital to have robust safeguards in place. This entails implementing measures such as data encryption and access controls, as well as promoting responsible data-sharing practices to maintain public trust and prevent misuse. The success of AI and ML models greatly depends on the quality and integrity of the data used to train them. In microbiology, the data often comes from a variety of sources, including genomic sequencing, imaging, and clinical records. If this data is inaccurate or poorly organized, it can lead to flawed AI models, which may impact the safety of diagnosis and treatment. Thus, we need to prioritize improving how we collect, label, and manage this data, along with investing in infrastructure that supports high-quality data flows. Another pressing issue is the lack of transparency and interpretability in many AI systems (Feng et al.,2023). While complex "black-box" models may yield highly accurate predictions, they often do so without any explanation of how decisions are made. This can undermine trust among microbiologists, clinicians, and patients. On the other hand, "white-box" models provide more understandable outputs but may not perform as well on complicated tasks. Finding a balance between model performance and clarity is crucial in clinical settings, where understanding how decisions are made is essential to responsible practice. Public perception and trust in AI technologies play a vital role in their successful implementation in healthcare and microbiology. Many patients still place a strong emphasis on human healthcare providers and might view AI with skepticism.

Concerns that AI may replace healthcare professionals or compromise the quality of care can hinder its adoption (Fu et al., 2021). It is essential to educate the public about the supportive role of AI, stressing that these tools are here to enhance, not replace, human expertise. While AI and ML are capable of transforming microbiology, realizing their full potential requires addressing various challenges. We need to address regulatory shortcomings, uphold ethical integrity, enhance data quality, promote transparency, and foster public trust to pave the way for the responsible and effective use of AI in both microbiological research and healthcare.

3.1 Case Studies and Notable Applications of AI in Microbiology

The application of artificial intelligence (AI) and machine learning (ML) in microbiology is progressing rapidly, providing valuable solutions to some of the most complex biological challenges we face in research, clinical practice, and industry. Several eye-opening case studies showcase how these technologies are making a real difference in the field. One key area where AI is making strides is in predicting antimicrobial resistance. Machine learning models are being trained to analyze genetic data—such as the presence or absence of specific genes and genetic variations—allowing researchers to predict how particular pathogens, like Escherichia coli, may resist multiple antibiotics. For instance, some models have successfully forecasted resistance patterns in different geographical regions by examining variations in genetic sequences (Gao et al.,2022). In other examples, researchers have cleverly combined various genomic data types—such as gene expression and single-nucleotide polymorphisms—to enhance the accuracy of their predictions, particularly for tough pathogens like Pseudomonas aeruginosa. These developments not only demonstrate the versatility of machine learning but also its potential to tackle the pressing global issue of antibiotic resistance effectively. In the realm of industrial microbiology, AI is being woven into quality control processes, improving the identification of microbial contaminants in sectors such as pharmaceuticals, cosmetics, and veterinary medicine. AI-powered computer vision and object detection tools are helping to monitor hygiene conditions more efficiently, ensuring products are safe for consumers. In the pharmaceutical industry, AI enhances drug safety and facilitates precise manufacturing processes (Ghosh et al.,2022). In cosmetics, it plays a crucial role in ensuring microbial purity and user safety. Additionally, in veterinary and food production settings, AI is contributing to product safety and quality, resulting in cost savings and enhanced operational efficiency. These applications demonstrate the increasing importance of AI in supporting public health and improving productivity across various industries. Another fascinating application of AI in microbiology is in the study of the human microbiome, a diverse collection of microbial communities that significantly impact our health. By utilizing AI and machine learning, researchers can more effectively analyze the relationship between changes in microbiome composition and specific health issues, such as inflammatory bowel disease and type 2 diabetes. This technology enables the prediction of how our microbial communities respond to various diets, medications, and environmental changes. By identifying biomarkers for diagnosis and prognosis, AI is paving the way for personalized treatment strategies (Goodswen et al.,2021). It also enables researchers to gain a deeper understanding of how imbalances in these microbial communities can impact various bodily processes. Overall, these case studies demonstrate the profound impact that AI and machine learning are having on the world of microbiology. Whether it is the fight against antibiotic resistance, enhancing industrial practices, or advancing diagnostic techniques based on microbiome research, AI is proving to be an invaluable ally in driving innovation. As research evolves and these technologies become more sophisticated, we can expect them to continue strengthening the fields of microbiology, public health, and personalized medicine.

3.2 Future Perspectives of AI and ML in Microbiology

The combination of artificial intelligence (AI) and machine learning (ML) in microbiology is opening up exciting possibilities for both research and practical applications. As these technologies advance, several critical trends and considerations will likely shape their growth and application in various fields of microbiology. One of the most promising developments is the growth of collaborative research networks. Currently, leading institutions such as the University of California, Harvard University, and the Chinese Academy of Sciences conduct a significant portion of the research (Habgood et al.,2023). However, many collaborations tend to stay within national or regional limits. Moving forward, it will be crucial to foster broader international partnerships. By working together globally, researchers can share knowledge, exchange data, and accelerate progress in understanding microbes, which is especially important in tackling global health issues. Another trend is the continued refinement of machine learning techniques. Recent advancements in algorithms have significantly enhanced our ability to predict phenomena such as antimicrobial resistance. As these tools become more advanced, future research will focus on refining machine learning methods to address challenges related to data quality and quantity. More reliable models will lead to better microbial classification, genome sequencing, and pathogen detection. Combining deep learning with specialized algorithms may also pave the way for personalized medicine and more efficient diagnostic tools (He et al.,2023). Despite the exciting potential, there are challenges to overcome for AI to be successfully and ethically integrated into microbiology. High-quality, standardized datasets are essential for training effective models. Additionally, fostering collaboration among microbiologists, data scientists, clinicians, and software engineers is vital in creating systems that



Figure 2. Sepsis, a severe response to infection, intensifies the urgency for effective treatment.

are accurate and applicable in real-world settings. Innovations in data annotation, validation, and standardized methods will help address any biases and improve the reproducibility of AI-driven research findings. Looking to the future, a collaborative approach that blends human expertise with AI capabilities will be essential. By bridging the gaps between fields and prioritizing transparency and trust, we can establish ethical and inclusive frameworks for utilizing AI in microbiology (Jolliffe et al., 2016). This teamwork will help solidify AI and ML as vital tools for understanding and managing microbial ecosystems, diseases, and their applications in various industries.

4. Discussion

The integration of artificial intelligence (AI) and machine learning (ML) into modern microbiology marks a transformative shift in how we generate, interpret, and apply microbial data in both clinical and research contexts. This intersection of advanced technologies with microbiological study is beginning to redefine traditional methodologies by enhancing the accuracy, speed, and scalability of microbial diagnostics. With these advancements, we can predict antimicrobial resistance, conduct genomic analyses, develop vaccines, and explore complex interactions in microbiome research (Kaufman et al.,2012). The potential benefits of adopting AI and ML in microbiology are immense, but they come with significant challenges and ethical considerations that must be navigated responsibly. It is essential to ensure that the transformative potential of these technologies is harnessed sustainably, prioritizing safety and ethical considerations alongside scientific advancement. One of the most significant applications of AI and ML in microbiology lies in genomic sequencing and microbial classification. AI tools possess the remarkable capability to analyze algorithms, researchers can uncover intricate patterns and connections within DNA sequences (Kaul et al.,2020). This capability is crucial for enhancing microbial taxonomy, identifying pathogenic variants, and supporting vital epidemiological investigations. As we incorporate these technologies into public health initiatives, the impact of AI and ML extends beyond research; it plays an essential role in real-time pathogen surveillance and outbreak prediction. In forensic microbiology, AI-based systems are already revolutionizing the field by automating the detection of diatoms and facilitating microbial forensic investigations. These tools provide law enforcement with rapid and reliable results, potentially transforming how microbial evidence is analyzed in criminal cases. Moreover, the efficiency of machine learning models in the early detection and prediction of antimicrobial resistance (AMR) addresses a pressing global health crisis. Numerous studies have demonstrated that ML models, when trained on genomic features such as single-nucleotide polymorphisms (SNPs), gene presence-absence data, and gene expression profiles, can accurately predict resistance phenotypes (Shan et al., 2021). These insights are invaluable; they aid healthcare professionals in formulating targeted treatment strategies while bolstering antibiotic stewardship initiatives.

The global landscape of healthcare is increasingly interconnected, and the ability of AI models to generalize findings across distinct geographical regions and microbial populations positions them as vital tools for global health surveillance and personalized medicine (Siddique et al.,2018). By understanding resistance mechanisms and bacterial behaviors, these models empower healthcare systems to respond proactively and effectively to antimicrobial challenges. Beyond diagnostics and resistance prediction, AI is making notable advancements in drug discovery and development. The process of identifying novel pharmaceutical compounds has historically faced numerous hurdles, including high failure rates in clinical trials (Tang et al.,2023). However, by analyzing extensive omics data alongside clinical parameters, AI platforms can pinpoint promising drug targets, predict drug efficacy, and mitigate the associated risks of clinical trial failures.

Drug repurposing is another area where AI systems excel, allowing researchers to identify new uses for existing medications. This not only accelerates the availability of effective treatments but also significantly lowers developmental costs and timelines. The innovative application of reinforcement learning techniques to simulate drug interactions and potential treatment outcomes further amplifies the possibilities of using AI in the development of new therapeutics. In the realm of industrial microbiology, AI technologies have become indispensable (Topçuoğlu et al.,2020). In pharmaceutical manufacturing, for instance, AI-powered systems help monitor and manage microbial contamination, ensuring compliance with rigorous safety standards while simultaneously optimizing production workflows. Similarly, in the food and cosmetics industries, AI plays a crucial role in maintaining microbial purity, enhancing product development, and safeguarding consumer safety. The operational efficiencies gained from these AI interventions reduce costs and minimize human error, rendering industrial processes more sustainable and reliable. AI technologies also hold pivotal importance in microbiome research and disease prediction. The human microbiome has a significant impact on health, influencing a range of conditions, from metabolic disorders to autoimmune and neurological diseases. By harnessing machine learning techniques, researchers can reveal correlations between different microbial communities and specific health outcomes. This knowledge can lead to predictive models that accurately forecast how individuals might respond to medications or dietary changes based on their unique microbiome composition (Tsuyuzaki et al.,2020). The implications of such personalized medical interventions are profound, presenting opportunities that were once merely theoretical. We are on the verge of possibly revolutionizing healthcare delivery systems through microbiome-based therapeutics, thereby enhancing diagnostic capabilities while paving the way for novel treatment options.

Despite the remarkable advancements driven by AI and ML in microbiology, the implementation of these technologies encounters significant hurdles. A primary concern is the quality and consistency of the data used to train AI systems. The effectiveness of these systems is intrinsically linked to the quality of the data they rely upon. However, microbiological data can often exhibit variability, incompleteness, or bias stemming from inconsistencies in sample collection, sequencing methods, and annotation practices. Such variability can jeopardize the performance and applicability of AI models, particularly when deployed across diverse populations or in varied laboratory contexts. Therefore, there is an urgent need for standardization in data generation and management processes. Investments in producing high-quality, well-annotated datasets are crucial for enhancing AI and ML applications in microbiology (Tufael et al., 2023).

Furthermore, ethical considerations must remain at the forefront of discussions surrounding the implementation of AI and ML in the microbiological sciences. The potential for bias in AI algorithms, stemming from imbalanced data sets, could exacerbate health disparities or lead to detrimental outcomes in patient care. A comprehensive understanding of these biases is paramount, necessitating rigorous scrutiny in both the development and application of AI-driven frameworks. Additionally, the issues of data privacy and security must be addressed, particularly when handling sensitive genomic information. Establishing robust ethical guidelines and regulatory frameworks will foster a safer environment for integrating AI in microbiology, paving the way for innovative breakthroughs that enhance our understanding and utilization of microbial data. The integration of AI and ML within the field of microbiology marks a watershed moment with profound implications for both research and clinical practice (Tufael et al.,2023). With their ability to enhance diagnostics, predict resistance, optimize drug discovery, and personalize treatment, these technologies present an unprecedented opportunity to improve health outcomes on a global scale. However, as we embrace these advancements, we must navigate the accompanying challenges with care and consideration. Establishing standard data practices, addressing ethical concerns, and ensuring data integrity will be crucial for realizing the full potential of AI and ML in microbiology. By doing so, we can forge a pathway toward a more sustainable, effective, and responsible future in the life sciences.

5. Conclusion

The application of artificial intelligence and machine learning in microbiology is revolutionizing the way research is conducted, diseases are diagnosed, and treatments are developed. These technologies enable us to analyze data in ways that were previously impossible, helping to detect pathogens, predict antimicrobial resistance, and tailor medicine to individual patients. However, embracing these advancements also presents challenges, such as ensuring data quality, addressing ethical issues, and maintaining public trust. To maximize the benefits of AI and ML in this field, experts from various disciplines must collaborate, focusing on developing ethical and transparent AI systems that enhance healthcare for everyone.

Author contributions

R.S.M. conceptualized the study, supervised the project, and contributed to manuscript writing. L.A. was responsible for data collection, analysis, and drafting the initial manuscript. M.N.A.B. assisted in data interpretation, literature review, and critical revision of the manuscript. All authors read and approved the final version of the manuscript.

Acknowledgment
The authors were grateful to their department.

Competing financial interests
The authors have no conflict of interest.

References

Ali, O., Farooq, A., Yang, M., Jin, V. X., Bjørås, M., Wang, J. (2022). abc4pwm: Affinity-based clustering for position weight matrices in applications of DNA sequence analysis. BMC Bioinf. 23, 83. doi: 10.1186/s12859-022-04615-z

Altman, N., Krzywinski, M. (2017). Clustering. Nat. Methods. 14, 545–546.

Alqaissi, E., Alotaibi, F., Sher Ramzan, M., Algarni, A. (2023). Novel graph-based machine-learning technique for viral infectious diseases: application to influenza and hepatitis diseases. Ann. Med.. 55, 2304108. doi: 10.1080/07853890.2024.2304108

Bao, Y., Medland, N. A., Fairley, C. K., Wu, J., Shang, X., Chow, E. P. F., et al. (2021). Predicting the diagnosis of HIV and sexually transmitted infections among men who have sex with men using machine learning approaches. J. Infect. 82, 48–59. doi: 10.1016/j.jinf.2020.11.007

Becht, E., McInnes, L., Healy, J., Dutertre, C. A., Kwok, I. W. H., Ng, L. G., et al. (2018). Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. 37, 38–44. doi: 10.1038/nbt.4314

Benincà, E., Pinto, S., Cazelles, B., Fuentes, S., Shetty, S., Bogaards, J. A., et al. (2023). Wavelet clustering analysis as a tool for characterizing community structure in the human microbiome. Sci. Rep. 13, 8042. doi: 10.1038/s41598-023-34713-8

Bergmeir, C., Benítez, J. M. (2012). On the use of cross-validation for time series predictor evaluation. Inf. Sci. 191, 192–213. Doi: 10.1016/j.ins.2011.12.028

Cammarota, G., Ianiro, G., Ahern, A., Carbone, C., Temko, A., Claesson, M. J., et al. (2020). Gut microbiome, big data, and machine learning to promote precision medicine for cancer. Nat. Rev. Gastroenterol. Hepatol. 17, 635–648. doi: 10.1038/s41575-020-0327-3

Campbell, T. W., Wilson, M. P., Roder, H., MaWhinney, S., Georgantas, R. W., 3rd, Maguire, L. K., et al. (2021). Predicting prognosis in COVID-19 patients using machine learning and readily available clinical data. Int. J. Med. Inform. 155, 104594.

Cao, J., Xiao, Y., Zhang, M., Huang, L., Wang, Y., Liu, W., et al. (2023). Deep learning of dual plasma fingerprints for high-performance infection classification. Small 19, e2206349. doi: 10.1002/smll.202206349

Chadaga, K., Chakraborty, C., Prabhu, S., Umakanth, S., Bhat, V., Sampathila, N. (2022). Clinical and laboratory approach to diagnose COVID-19 using machine learning. Interdiscip Sci. 14, 452–470. doi: 10.1007/s12539-021-00499-4

Chen, X., Ren, B., Chen, M., Wang, Q., Zhang, L., Yan, G. (2016). NLLSS: Predicting synergistic drug combinations based on semi-supervised learning. PloS Comput. Biol. 12, e1004975. Doi: 10.1371/journal.pcbi.1004975

David, J. A., Zhichao, A., Mark, A., Chris, A., Allcock, A., Brian, A., et al. (2022). A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell 185, 916–938.e58.

Dawkins, J. J., Allegretti, J. R., Gibson, T. E., McClure, E., Delaney, M., Bry, L., et al. (2022). Gut metabolites predict Clostridioides difficile recurrence. Microbiome 10, 87. doi: 10.1186/s40168-022-01284-1

De Fátima Cobre, A., Surek, M., Stremel, D. P., Fachi, M. M., Lobo Borba, H. H., Tonin, F. S., et al. (2022). Diagnosis and prognosis of COVID-19 employing analysis of patients' plasma and serum via LC-MS and machine learning. Comput. Biol. Med.. 146, 105659.

Delafiori, J., Navarro, L. C., Siciliano, R. F., de Melo, G. C., Busanello, E. N. B., Nicolau, J. C., et al. (2021). COVID-19 automated diagnosis and risk assessment through metabolomics and machine learning. Anal. Chem. 93, 2471–2479. doi: 10.1021/acs.analchem.0c04497

Deo, R. C. (2015). Machine learning in medicine. Circulation 132, 1920–1930. doi: 10.1161/CIRCULATIONAHA.115.001593

Essalat, M., Abolhosseini, M., Le, T. H., Moshtaghion, S. M., Kanavi, M. R. (2023). Interpretable deep learning for diagnosis of fungal and acanthamoeba keratitis. Vivo confocal microscopy images Sci. Rep. 13, 8953.

Fabian, P., Gaël, V., Alexandre, G., Vincent, M., Bertrand, T., Olivier, G., et al. (2011). Scikit-learn: Machine Learning in Python. J. Mach. Learn. Res. 12, 2825–2830.

Feng, T., Noren, D. P., Kulkarni, C., Mariani, S., Zhao, C., Ghosh, E., et al. (2023). Machine learning-based clinical decision support for infection risk prediction. Front. Med. 10.

Fu, C., Zhang, X., Veri, A. O., Iyer, K. R., Lash, E., Xue, A., et al. (2021). Leveraging machine learning essentiality predictions and chemogenomic interactions to identify antifungal targets. Nat. Commun. 12 (1), 6497.

Gao, A., Kouznetsova, V. L., Tsigelny, I. F. (2022). Machine-learning-based virtual screening to repurpose drugs for the treatment of Candida albicans infection. Mycoses 65, 794–805. doi: 10.1111/myc.13475

Ghosh, S., Sarkar Paria, D., Chatterjee, S. (2022). Comparative study on bacterial population dynamics of foregut, midgut, and hindgut content of Perionyx excavatus (Perrier) isolated from eco-friendly, non-hazardous vermicompost. Appl. Biochem. Biotechnol. 194, 6126–6139. doi: 10.1007/s12010-022-03970-0

Goodswen, S. J., Barratt, J. L. N., Kennedy, P. J., Kaufer, A., Calarco, L., Ellis, J. T. (2021). Machine learning and applications in microbiology. FEMS Microbiol. Rev. 45, fuab015. doi: 10.1093/femsre/fuab015

Habgood-Coote, D., Wilson, C., Shimizu, C., Barendregt, A. M., Philipsen, R., Galassini, R., et al. (2023). Diagnosis of Childhood Febrile Illness Using a Multiclass Blood RNA Molecular Signature. Med 4, 635–654.e5. doi: 10.1016/j.medj.2023.06.007

He, X., Qian, K., Wang, Z., Zeng, S., Li, H., Li, W. V. (2023). scAce: an adaptive embedding and clustering method for single-cell gene expression data. Bioinf. 39 btad546. doi: 10.1093/bioinformatics/btad546

Jolliffe, I. T., Cadima, J. (2016). Principal component analysis: a review and recent developments. Philos. Trans. A Math Phys. Eng. Sci. 374, 20150202. doi: 10.1098/rsta.2015.0202

Kaufman, S., Rosset, S., Perlich, C., Stitelman, O. (2012). Leakage in data mining: Formulation, detection, and avoidance. ACM Trans. Knowl. Discovery Data 6, 1–21. doi: 10.1145/2382577.2382579

Kaul, V., Enslin, S., Gross, S. A. (2020). History of artificial intelligence in medicine. Gastrointest Endosc 92, 807–812. doi: 10.1016/j.gie.2020.06.040

Shan, W., Li, X., Yao, H., Lin, K. (2021). Convolutional neural network-based virtual screening. Curr. Med. Chem. 28, 2033–2047. doi: 10.2174/0929867327666200526142958

Siddique, M. A. B., Debnath, A., Nath, N. D., Biswash, M. A. R., Tufael (2018). "Advancing Medical Science through Nanobiotechnology: Prospects, Applications, and Future Directions", Journal of Primeasia, 1.1(1),1-7,10163

Tang, Y., Wang, S., Qu, Y., Cui, Z., Zhang, W. (2023). Consistency and adversarial semi-supervised learning for medical image segmentation. Comput. Biol. Med. 161, 107018. doi: 10.1016/j.compbiomed.2023.107018

Topçuoğlu, B. D., Lesniak, N. A., Ruffin, M. T., Wiens, J., Schloss, P. D. (2020). A framework for effective application of machine learning to microbiome-based classification problems. mBio 11, e00434–e00420. doi: 10.1128/mBio.00434-20

Tsuyuzaki, K., Sato, H., Sato, K., Nikaido, I. (2020). Benchmarking principal component analysis for large-scale single-cell RNA-sequencing. Genome Biol. 21 (1), 9.

Tufael, Atiqur Rahman Sunny et al. (2023). Artificial Intelligence in Addressing Cost, Efficiency, and Access Challenges in Healthcare, 4(1), 1-5, 9798

Tufael & Atikur Rahman Sunnay (2022). Transforming Healthcare with Artificial Intelligence: Innovations, Applications, and Future Challenges, Journal of Primeasia, 3(1), 1–6, 9802

Yang, Y., Xu, B., Murray, J., Haverstick, J., Chen, X., Tripp, R. A., et al. (2022). Rapid and quantitative detection of respiratory viruses using surface-enhanced Raman spectroscopy and machine learning. Biosens Bioelectron 217, 114721. doi: 10.1016/j.bios.2022.114721

Zacher, B., Czogiel, I. (2022). Supervised learning using routine surveillance data improves outbreak detection of Salmonella and Campylobacter infections in Germany. PloS One 17, e0267510. doi: 10.1371/journal.pone.02675106, 9802

Tufael, Atiqur Rahman Sunny et al. (2023). Artificial Intelligence in Addressing Cost, Efficiency, and Access Challenges in Healthcare, 4(1), 1-5, 9798

Wan TT, Wan HS. (2023). Predictive analytics with a transdisciplinary framework in promoting patient-centric care of polychronic conditions: Trends, challenges, and Solutions. AI. Jul 13;4(3):482-90.

Yadav P, Arora N, Sharma SC. (2023). Performance Analysis of Nature-Inspired Optimization Algorithms for Chronic Disease Prediction. In2023 International Conference on Device Intelligence, Computing and Communication Technologies, (DICCT), Mar 17 (pp. 1-6). IEEE.

Zafar I, Anwar S, Yousaf W, Nisa FU, Kausar T, ul Ain Q, Unar A, Kamal MA, Rashid S, Khan KA, Sharma R. (2023). Reviewing methods of deep learning for intelligent healthcare systems in genomics and biomedicine. Biomedical Signal Processing and Control. Sep 1;86:105263.

Zhuhadar LP, Lytras MD.(2023). The application of AutoML techniques in diabetes diagnosis: current approaches, performance, and future directions. Sustainability. Sep 8;15(18):13484.